
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global HIV Drugs Market Snapshot
Chapter 4. Global HIV Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Clinical Trial/Pipeline Analysis
4.5. Industry Analysis – Porter’s Five Forces Analysis
4.6. Clinical Trial Analysis 2019
4.7. COVID 19 Impact Analysis
Chapter 5. Market Segmentation 1: Drug Type Estimates & Trend Analysis
5.1. Drug Type & Market Share, 2025 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Drug Type:
5.2.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
5.2.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
5.2.3. Protease Inhibitors (PIs)
5.2.4. Integrase Inhibitors
5.2.5. Entry and Fusion Inhibitors
5.2.6. Combination Class Drugs
Chapter 6. Market Segmentation 2: Distribution Channel Estimates & Trend Analysis
6.1. Distribution Channel & Market Share, 2025 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Distribution Channel:
6.2.1. Hospital Pharmacies
6.2.2. Retail Pharmacies
6.2.3. Online Pharmacies
Chapter 7. HIV Drugs Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America HIV Drugs Market revenue (US$ Million) estimates and forecasts by drug type, 2022 to 2035
7.1.1. North America HIV Drugs Market revenue (US$ Million) estimates and forecasts by distribution channel, 2022 to 2035
7.1.2. North America HIV Drugs Market revenue (US$ Million) estimates and forecasts by country, 20
7.1.2.1. U.S.
7.1.2.2. Canada
7.2. Europe
7.2.1. Europe HIV Drugs Market revenue (US$ Million) by drug type, 2022 to 2035
7.2.1. Europe HIV Drugs Market revenue (US$ Million) by distribution channel, 2022 to 2035
7.2.2. Europe HIV Drugs Market revenue (US$ Million) by country, 2022 to 2035
7.2.2.1. Germany
7.2.2.2. Poland
7.2.2.3. France
7.2.2.4. Italy
7.2.2.5. Spain
7.2.2.6. UK
7.2.2.7. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Pacific HIV Drugs Market revenue (US$ Million) by drug type, 2022 to 2035
7.3.1. Asia Pacific HIV Drugs Market revenue (US$ Million) by distribution channel, 2022 to 2035
7.3.2. Asia Pacific HIV Drugs Market revenue (US$ Million) by country, 2022 to 2035
7.3.2.1. China
7.3.2.2. India
7.3.2.3. Japan
7.3.2.4. Australia
7.3.2.5. Rest of Asia Pacific
7.4. Latin America
7.4.1. Latin America HIV Drugs Market revenue (US$ Million) by drug type, (US$ Million) 2022 to 2035
7.4.1. Latin America HIV Drugs Market revenue (US$ Million) by distribution channel, (US$ Million) 2022 to 2035
7.4.2. Latin America HIV Drugs Market revenue (US$ Million) by country, (US$ Million) 2022 to 2035
7.4.2.1. Brazil
7.4.2.2. Rest of Latin America
7.5. MEA
7.5.1. MEA revenue HIV Drugs Market revenue (US$ Million) by drug type, (US$ Million) 2022 to 2035
7.5.1. MEA revenue HIV Drugs Market revenue (US$ Million) by distribution channel, (US$ Million) 2022 to 2035
7.5.2. MEA revenue HIV Drugs Market revenue (US$ Million) by country, (US$ Million) 2022 to 2035
7.5.2.1. South Africa
7.5.2.2. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Gilead Sciences
8.2.2. ViiV Healthcare
8.2.3. Janssen
8.2.4. Bristol-Myers Squibb
8.2.5. TaiMed Biologics
8.2.6. CytoDyn
8.2.7. Boehringer Ingelheim International GmbH
8.2.8. Merck & Co. Inc.
8.2.9. AbbVie
8.2.10. F. Hoffmann-La Roche Ltd.
8.2.11. Teva Pharmaceutical Industries Ltd.
8.2.12. Cipla Limited
8.2.13. Daiichi Sankyo
8.2.14. Emcure
8.2.15. Hetero Drugs
8.2.16. Mylan
8.2.17. Shantou Huatai Pharmaceutical Co., Ltd.
8.2.18. Shengzhen Chongway Biotechnology Co., Ltd.
8.2.19. Other Prominent Player
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.